Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 119 от 154

Активно (без набиране) Фаза 3

Preventing Cognitive Decline with Metformin

Cognitive Decline

A randomised control study of metformin in people with mild cognitive impairment and without diabetes mellitus to determine effects on cognitive decline and neuroimaging over 3 years.

Начало: 15.07.2022 Край: 01.12.2027 Възраст: 60–80 г. Лечение

Australia Garvan Institute of Medical Research NCT04511416

Активно (без набиране) Фаза 1/2

Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer mCRPC

This clinical trial will evaluate the safety of Cabazitaxel in combination with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer.

Начало: 14.07.2022 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia Peter MacCallum Cancer Centre, Australia NCT05340374

Активно (без набиране) Фаза 2

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

The purpose of this study is to learn about the effects of three study medicines (encorafenib, cetuximab, and pembrolizumab) given together for the treatment of colorectal cancer that: * is metastatic (spread to other parts of the body); * has the condition of genetic hypermutability (tendency to mutation) or impaired DNA mismatch repair (MMR) * has a certain type of abnormal gene called "BRAF" and; * has not received prior treatment. All participants in this study will receive pembrolizumab at the study clinic as an intravenous (IV) infusion (given directly into a vein) at the study clinic. In addition, half of the participants will take encorafenib by mouth at home every day and cetuximab by IV infusion at the study clinic. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

Начало: 11.07.2022 Край: 26.01.2027 Възраст: от 16 г. Лечение

Australia, Belgium, Canada +11 Pfizer NCT05217446

Активно (без набиране) Фаза 3

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Coronary Artery Disease

CKJX839D12303 is a research study to determine if the study treatment, called inclisiran, in comparison to placebo taken in addition to statin medication can effectively reduce the total amount of plaque formed in the heart's vessels as measured by coronary computed tomography angiography (CCTA) from baseline to month 24. This study is being conducted in eligible participants with a diagnosis of non-obstructive coronary artery disease (NOCAD), where the coronary arteries are blocked less than 50%, and with no previous cardiovascular events.

Начало: 08.07.2022 Край: 26.10.2026 Възраст: 18–80 г. Лечение

Argentina, Australia, Belgium +15 Novartis Pharmaceuticals NCT05360446

Активно (без набиране) Фаза 3

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Nonsquamous Non-small Cell Lung Cancer EGFR L858R EGFR Exon 19 Deletion

Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile.There is an urgent need for more effective and tolerable therapies for patients with EGFRm NSCLC who have exhausted available targeted therapies. Clinical evidence suggest that patritumab deruxtecan constitutes a promising investigational therapy for patients with EGFRm NSCLC.

Начало: 08.07.2022 Край: 30.06.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +16 Daiichi Sankyo NCT05338970

Активно (без набиране)

Natural History of PRPF31 Mutation-Associated Retinal Dystrophy

Retinitis Pigmentosa Eye Diseases, Hereditary Retinal Dystrophies Retinal Dystrophy Rod +1

The purpose of this study is to characterize the natural history through temporal systemic evaluation of subjects identified with PRPF31 mutation-associated retinal dystrophy, also called retinitis pigmentosa type 11, or RP11. Assessments will be completed to measure and evaluate structural and functional visual changes including those impacting patient quality of life associated with this inherited retinal condition and observing how these changes evolve over time.

Начало: 07.07.2022 Край: 01.11.2026 Възраст: от 10 г.

Australia, United States PYC Therapeutics NCT05573984

Активно (без набиране) Фаза 1/2

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

Metastatic Uveal Melanoma

This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations.

Начало: 04.07.2022 Край: 01.10.2027 Възраст: 18–100 г. Лечение

Australia, France, Germany +4 Novartis Pharmaceuticals NCT05415072

Активно (без набиране)

Long-term Use of CCB and Breast Cancer Risk

Hypertension,Essential Breast Cancer

The goal of this retrospective observational study is to examine whether long-term calcium channel blocker (CCB) use is associated with the development of breast cancer amongst women enrolled in three longitudinal cohort studies in Australia and the Netherlands . The main questions it aims to answer are: * Is long-term CCB use associated with the development of breast cancer amongst women enrolled in three longitudinal cohort studies in Australia and the Netherlands and what is the dose-response nature of this association. * Does differences in the association between calcium channel blocker use and the development of breast cancer exist between Australian and Dutch women. The investigators will utilise data from the Australian Longitudinal Study on Women's Health (ALSWH) , 45 and Up Study and Rotterdam study.

Начало: 01.07.2022 Край: 01.12.2025 Възраст: от 45 г.

Australia Curtin University NCT05972785

Активно (без набиране) Фаза 3

Phase III Trial of Sirolimus in IBM

Inclusion Body Myositis

The hypothesis is that Sirolimus, (Rapamycin (R)) which is currently used in organ transplantation and works by blocking the activity of T effector cells but preserving T regulatory cells, as well as by inducing autophagy (protein degradation), will be effective in IBM to slow or stabilize disease progression, helping to maintain patient function and independence. This phase III trial will confirm pilot data showing statistically significant clinical outcomes.

Начало: 01.07.2022 Край: 01.12.2027 Възраст: от 45 г. Лечение

Australia, Netherlands, United States University of Kansas Medical Center NCT04789070

Активно (без набиране)

Sex-specific Risk Factors and Trajectories of Blood Biomarkers for Alzheimer's Disease and Related Dementias

Alzheimer Disease Dementia Cognitive Dysfunction

Blood-based ADRD biomarkers show tremendous promise as a non-invasive method to predict and diagnose ADRD. We will measure changes in these biomarkers to determine whether their ability to predict ADRD differs by sex or by other characteristics, and develop a sex-specific ADRD risk score for personalized medicine and clinical trials.

Начало: 01.07.2022 Край: 01.08.2027 Възраст: от 65 г.

Australia, United States Anne Murray NCT07224139

Активно (без набиране) Фаза 3

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

Pterygium

The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle in reducing conjunctival hyperemia and preventing pterygium progression in eyes with pterygia.

Начало: 30.06.2022 Край: 31.12.2027 Възраст: от 12 г. Лечение

Australia, China, India +2 Cloudbreak Therapeutics, LLC NCT05456425

Активно (без набиране) Фаза 3

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

Psoriatic Arthritis

An open label phase 3 study

Начало: 30.06.2022 Край: 01.04.2029 Възраст: от 18 г. Лечение

Australia, Canada, Czechia +11 Sun Pharmaceutical Industries Limited NCT04991116

Активно (без набиране) Фаза 1

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Non-Small Cell Lung Cancer (NSCLC) Metastatic Non-Small Cell Lung Cancer Advanced Non-Small Cell Lung Cancer HER2 Exon 20 Mutations +2

This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating, including uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) mutations. Patients will be enrolled into one of 2 stages: Stage 1 (Dose Escalation and Backfill Cohorts) and Stage 2 (Dose Expansion).

Начало: 30.06.2022 Край: 31.12.2026 Възраст: от 18 г. Лечение

Australia, Canada, China +8 ArriVent BioPharma, Inc. NCT05364073

Активно (без набиране) Фаза 3

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Ovarian Neoplasm Fallopian Tube Neoplasms Peritoneal Neoplasms

The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of Relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.

Начало: 29.06.2022 Край: 01.03.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +11 Corcept Therapeutics NCT05257408

Активно (без набиране) Фаза 1/2

A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety, pharmacokinetics (PK), and preliminary anti-tumor activity of TAC-001 administered intravenously.

Начало: 28.06.2022 Край: 19.05.2026 Възраст: от 18 г. Лечение

Australia, United States Tallac Therapeutics NCT05399654

Активно (без набиране) Фаза 2

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

SSM Mastocytosis, Indolent Mastocytosis, Systemic Mastocytosis +4

This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 clinical study comparing the safety and efficacy of bezuclastinib (CGT9486) plus best supportive care (BSC) with placebo plus BSC in patients with nonadvanced systemic mastocytosis (NonAdvSM), including indolent systemic mastocytosis and smoldering systemic mastocytosis, whose symptoms are not adequately controlled by BSC. This study will be conducted in three parts. Patients in Parts 1a, 1b and 2 will receive bezuclastinib or placebo, and may roll over onto Part 3 to receive treatment with bezuclastinib. Additionally, a substudy of subjects will investigate the efficacy, safety, and tolerability of bezuclastinib in patients who are experiencing inadequate symptom control with avapritinib.

Начало: 27.06.2022 Край: 01.04.2030 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +12 Cogent Biosciences, Inc. NCT05186753

Активно (без набиране) Фаза 3

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

Plasma Cell Myeloma Recurrent

This is a randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study participants) who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI). Eligible participants will be randomized 1:1 into 1 of 2 study arms: Arm SC: Isatuximab SC + Pd Arm IV: Isatuximab IV + Pd Participants will be allowed to continue therapy until disease progression, unacceptable adverse events (AEs), participant request to discontinue therapy or any other reason, whichever comes first.

Начало: 23.06.2022 Край: 23.03.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +18 Sanofi NCT05405166

Активно (без набиране)

Merit WRAPSODY™ Endoprosthesis for Treatment of Stenosis or Occlusion (WRAP)

Venous Stenosis Venous Occlusion

The WRAP Study aims to expand and understand the safety and efficacy data on the WRAPSODY Endoprosthesis System in a real-world population.

Начало: 23.06.2022 Край: 15.10.2027 Възраст: от 18 г.

Australia, Brazil, Germany +6 Merit Medical Systems, Inc. NCT05062291

Активно (без набиране) Фаза 3

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Multiple Myeloma

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).

Начало: 23.06.2022 Край: 25.06.2032 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +24 Celgene NCT04975997

Активно (без набиране)

ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

Aortic Stenosis, Severe

The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific aortic stenosis (AS).

Начало: 20.06.2022 Край: 01.12.2034 Лечение

Australia, Canada, New Zealand +1 Edwards Lifesciences NCT05172960

1 … 117 118 119 120 121 … 154